Superworth

NEUROONE MEDICAL TECHNOLOGIES profit margin NMTC

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
−78.6%
Operating margin, 12 months
−83.4%
Net margin on a year earlier
+1.9 pts
Peer median
7.6%

Over the twelve months to Jun 30, 2026, NEUROONE MEDICAL TECHNOLOGIES kept −78.6% of its revenue as net profit, with an operating margin of −83.4% and a gross margin of 55.6%.

The median for 5 healthcare stocks of a similar size is 7.6%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−39.6%−46.5%56.5%
FY2024n/an/a31.3%
FY2023n/an/a23.4%
FY2022n/an/a−41.4%
FY2021n/an/a−54.9%
FY2020n/an/an/a
FY2019n/an/an/a
FY2018n/an/an/a
FY2017n/an/an/a
FY2016n/an/an/a
FY2015n/an/an/a
FY2014n/an/an/a
FY2013n/an/an/a
FY2012n/an/an/a
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−78.6%+1.9 pts−83.4%
Q2 FY26−75.5%n/a−80.1%
Q1 FY26−78.3%n/a−87.7%
Q4 FY25−39.6%n/a−46.5%
Q3 FY25−80.5%n/a−85.6%
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a

Against its peers

Companies in Healthcare nearest NEUROONE MEDICAL TECHNOLOGIES' size, closest first, today.

CompanyProfit margin
NMTCNEUROONE MEDICAL TECHNOLOGIES−78.6%
NEPHNephros8.4%
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech6.8%
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
Peer median7.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on NEUROONE MEDICAL TECHNOLOGIES

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.